The radioligand therapy was linked with a significant increase in progression-free survival and a clinically relevant increase in overall survival in patients with midgut neuroendocrine tumours
Read More
A price cut has secured NHS funding for Advanced Accelerator Applications’ Lutathera as a treatment for some neuroendocrine tumours (NETs).
Read More
Three treatments have been approved for NHS funding in Scotland, bringing new options for gastroenteropancreatic tumours, lung and kidney cancers, but patients with multiple sclerosis will be unable to access Roche’s Ocrevus following a rejection by the SMC.
Read More
US regulators have cleared the use of Novartis group Advanced Accelerator Applications’ Lutathera to treat certain gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Read More
Novartis has unveiled plans to buy Advanced Accelerator Applications (AAA) for $3.9 billion in cash, beefing up its oncology portfolio.
Read More
Eleven therapies, including five targeting rare diseases, have taken a giant leap towards being approved in Europe after winning backing from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
